stockportfolio.pro
AMGN vs DHR: Which Stock Is the Better Buy?
Amgen Inc. and Danaher Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — AMGN vs DHR, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Amgen Inc. (AMGN) | Danaher Corporation (DHR) | |
|---|---|---|
| Market cap | $201.9B | $140.1B |
| Revenue (latest FY) | $36.75B | $24.57B |
| Net income (latest FY) | $7.71B | $3.61B |
| Revenue growth (5y CAGR) | 7.6% | 2.0% |
| Net margin | 21.0% | 14.7% |
| Return on equity | 89.1% | 6.9% |
| P/E ratio | 26.0 | 38.3 |
| Dividend yield | 2.7% | 0.8% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
See the full AMGN vs DHR breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AMGN's full financials → Open DHR's full financials →More comparisons
Frequently asked questions
Which is bigger, AMGN or DHR?
Amgen Inc. is larger by market capitalization — $201.9B versus $140.1B.
Which grows faster, AMGN or DHR?
Over the last five fiscal years, Amgen Inc. grew revenue faster — 7.6%/yr versus 2.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.